Merck (MRK) Other Non-Current Liabilities (2009 - 2026)
Merck (MRK) posted quarterly Other Non-Current Liabilities of $7.6 billion for Q1 2026, up 14.83% year-over-year from $6.7 billion in Q1 2025, and down 0.6% quarter-over-quarter from $7.7 billion in Q4 2025.
Merck (MRK) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Other Non-Current Liabilities for 17 consecutive years, with $7.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 14.83% year-over-year to $7.6 billion; the TTM figure through Mar 2026 stood at $7.6 billion (up 14.83% YoY), while the FY2025 annual figure was $7.7 billion, up 18.92% from the prior year.
- Other Non-Current Liabilities retreated to $7.6 billion in Q1 2026 per MRK's latest filing, from $7.7 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.7 billion in Q1 2022 and bottomed at $208.0 million in Q3 2024.
- Historically, Other Non-Current Liabilities has averaged $4.2 billion across 5 years, with a median of $6.5 billion in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities plunged 97.17% — and 2025, when it jumped 3583.17%.
- Merck's Other Non-Current Liabilities stood at $8.3 billion in 2022, then sank by 95.75% to $354.0 million in 2023, then soared by 1726.27% to $6.5 billion in 2024, then rose by 18.92% to $7.7 billion in 2025, then decreased by 0.6% to $7.6 billion in 2026.
- Business Quant data shows MRK's Other Non-Current Liabilities at $7.6 billion in Q1 2026, $7.7 billion in Q4 2025, and $7.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.57 Bn |
| Mar 31, 2026 | 7.64 Bn |
| Dec 31, 2025 | 7.69 Bn |
| Sep 30, 2025 | 7.66 Bn |
| Jun 30, 2025 | 7.03 Bn |
| Mar 31, 2025 | 6.66 Bn |
| Dec 31, 2024 | 6.47 Bn |
| Sep 30, 2024 | 208.00 Mn |
| Jun 30, 2024 | 225.00 Mn |
| Mar 31, 2024 | 226.00 Mn |
| Dec 31, 2023 | 354.00 Mn |
| Sep 30, 2023 | 7.34 Bn |
| Jun 30, 2023 | 349.00 Mn |
| Mar 31, 2023 | 353.00 Mn |
| Dec 31, 2022 | 8.32 Bn |
| Sep 30, 2022 | 499.00 Mn |
| Jun 30, 2022 | 542.00 Mn |
| Mar 31, 2022 | 9.74 Bn |
| Dec 31, 2021 | 777.00 Mn |
| Sep 30, 2021 | 902.00 Mn |